威高股份(01066)第三季度收入约32.6亿元 同比增长约2.6%

Core Viewpoint - Weigao Group (01066) reported an unaudited revenue of approximately RMB 3.26 billion for the three months ending September 30, 2025, representing a year-on-year growth of about 2.6% [1] Revenue Breakdown - The orthopedic, interventional, and blood management segments experienced rapid revenue growth [1] - The pharmaceutical packaging and general medical device segments faced pressure on sales prices due to policy impacts, which negatively affected the overall revenue growth of the group [1]